Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | HPGD | P15428 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | ILK | Q13418 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | NPY1R | P25929 | 1/20 | 0.39 |
| ▸ | NPY2R | P49146 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8287133 | 0.90 | ALDH1A1 (0.43) | CSF1RKDM4EALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL8287147 | 0.89 | HTT (0.44) | CSF1RHTTALDH1A1SMN1; SMN2ELANE | |
| SCHEMBL8287373 | 0.87 | PDE11A (0.40) | CSF1RKDM4EHTTALDH1A1HPGD | |
| SCHEMBL8287383 | 0.86 | PDE11A (0.41) | CSF1RALDH1A1HPGDSMN1; SMN2MEN1 | |
| SCHEMBL8287382 | 0.86 | PDE11A (0.43) | CSF1RALDH1A1MAPTGAA | |
| SCHEMBL8285199 | 0.84 | CSF1R (0.47) | CSF1RKDM4EHTTALDH1A1HPGD | |
| SCHEMBL5871780 | 0.84 | PDE11A (0.41) | CSF1RALDH1A1ILKKMT2AMAPT | |
| SCHEMBL5871882 | 0.82 | CSF1R (0.48) | CSF1RKDM4EHTTALDH1A1HPGD | |
| SCHEMBL8287374 | 0.82 | PDE11A (0.40) | CSF1RKDM4EHTTALDH1A1HPGD | |
| SCHEMBL5872009 | 0.81 | PDE11A (0.44) | KDM4EHTTALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109196-B2 | 1,8 Naphthyridine derivatives and their use to treat diabetes and related disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-09-19 | — | — | US | disclosed |
| US-20060189609-A1 | 1, 8-Naphthyridine derivatives and their use to treat diabetes and related disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-08-24 | — | — | US | disclosed |
| US-6964971-B2 | 1,6-naphthyridine derivatives and their use to treat diabetes and related disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-11-15 | — | — | US | disclosed |
| WO-2005091857-A2 | 1,6-NAPHTHYRIDINE AND 1,8-NAPHTHYRIDINE DERIVATIVES AND THEIR USE TO TREAT DIABETES AND RELATED DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-10-06 | — | — | WO | disclosed |
| WO-2005091857-A2 | 1,6-NAPHTHYRIDINE AND 1,8-NAPHTHYRIDINE DERIVATIVES AND THEIR USE TO TREAT DIABETES AND RELATED DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-10-06 | — | — | WO | disclosed |
| US-6900205-B2 | 1,8-Naphthyridine derivatives and their use to treat diabetes and related disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-05-31 | — | — | US | disclosed |
| US-20040209866-A1 | 1,8 Naphthyridine derivatives and their use to treat diabetes and related disorders | BAYER PHARMACEUTICALS CORPORATION | 2004-10-21 | — | — | US | disclosed |
| US-20040157875-A1 | 1, 6-Naphthyridine derivatives and their use to treat diabetes and related disorders | BAYER PHARMACEUTICALS CORPORATION | 2004-08-12 | — | — | US | disclosed |
| EP-1432710-A1 | 1, 8-NAPHTHYRIDINE DERIVATIVES AS ANTIDIABETICS | Bayer Pharmaceuticals Corporation (US) | 2004-06-30 | — | — | EP | disclosed |
| EP-1432711-A1 | 1,6-NAPHTHYRIDINE DERIVATIVES AS ANTIDIABETICS | Bayer Corporation (US) | 2004-06-30 | — | — | EP | disclosed |
| US-20040014751-A1 | 1,8-Naphthyridine derivatives and their use to treat diabetes and related disorders | BAYER CORPORATION | 2004-01-22 | — | — | US | disclosed |
| US-6677352-B1 | 1,6-naphthyridine derivatives and their use to treat diabetes and related disorders | BAYER PHARMACEUTICALS CORPORATION | 2004-01-13 | — | — | US | disclosed |
| WO-2003027112-A1 | 1, 8-NAPHTHYRIDINE DERIVATIVES AS ANTIDIABETICS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| WO-2003027112-A1 | 1, 8-NAPHTHYRIDINE DERIVATIVES AS ANTIDIABETICS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| WO-2003027113-A1 | 1,6-NAPHTHYRIDINE DERIVATIVES AS ANTIDIABETICS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157875-A1 | 1, 6-Naphthyridine derivatives and their use to treat diabetes and related disorders | GLP1R, NQO1, UQCRC1 | CSF1R 2698/4885KDM4E 1967/4885HTT 1221/4885 |
| US-20040209866-A1 | 1,8 Naphthyridine derivatives and their use to treat diabetes and related disorders | SLC5A1, NQO1, GLP1R | CSF1R 2974/4885KDM4E 2011/4885HTT 1745/4885 |
| US-20040014751-A1 | 1,8-Naphthyridine derivatives and their use to treat diabetes and related disorders | UQCRC1, GLP1R, SLC5A1 | CSF1R 3037/4885KDM4E 2115/4885HTT 1760/4885 |
| US-20060189609-A1 | 1, 8-Naphthyridine derivatives and their use to treat diabetes and related disorders | GLP1R, UQCRC1, SLC5A1 | CSF1R 3131/4885KDM4E 1934/4885HTT 1566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.